This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Citi Board Nominates Franz B. Humer And Joan E. Spero To Board Of Directors

Citi's Board of Directors today announced that it has nominated Franz B. Humer and Joan E. Spero as new independent director candidates to stand for election at Citi's annual meeting of stockholders on April 17, 2012. Dr. Humer is Chairman of Roche Holding Ltd, and Ms. Spero is a Senior Research Scholar at Columbia University School of International Public Affairs.

"We are pleased to nominate Franz Humer and Joan Spero to the slate of candidates for Citi’s Board of Directors,” said Richard D. Parsons, Chairman of the Board of Directors of Citi. “Dr. Humer’s expertise in international and consumer business as well as his many years of experience leading large organizations in the U.S. and Europe make him an excellent candidate for the board. And we look forward to tapping the vast experience Ms. Spero will bring as a leader in government and international business as well as her knowledge of regulatory compliance and corporate governance issues. Both candidates will bring considerable insight to the Board as Citi continues to grow internationally and build on its unmatched global strengths.”

“Throughout our history, Citi has looked across international borders and helped connect the world for our clients,” said Vikram Pandit, Chief Executive Officer of Citi. “While we’ve returned to our core strengths of providing banking services to our clients, we continue to see international growth as our greatest opportunity and our global footprint as our greatest strength. These two candidates for the board have a deep understanding of the challenges and opportunities we face as we continue to execute our global growth plans.”

Franz B. Humer

Dr. Humer, 65, is the Chairman of Roche Holding Ltd and served as Chief Executive Officer of the Roche Group from 1998 until 2008. He previously served as Chief Operating Officer and Head of Pharmaceuticals for F. Hoffmann-La Roche Ltd. Dr. Humer is Chairman of Diageo plc. Dr. Humer is the chairman of Friends of Phelophepa Foundation, the chairman of INSEAD and chairman of the International Centre for Missing and Exploited Children. He is a member of the European Round Table of Industrialists, a member of the board of Salzburg University and a member of the board of Jacobs Holding AG.

Stock quotes in this article: C 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs